Akari Therapeutics PLC (AKTX NASDAQ) stock market data APIs
$3.457
0.47(13.6%)
as of May 20, 2026
Try our APIs with
free plan!
Akari Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Prev. Close
3.457
Open
3.9284
High
3.9583
Low
3.4098
52 wk Range
3.015-56.8
Market Cap
4 201 K
P/E Ratio
0
Shares Outstanding
1 145 K
Beta
0.648
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akari Therapeutics PLC data using free add-ons & libraries
Get Akari Therapeutics PLC Fundamental Data
Akari Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -12 081 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: -2.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akari Therapeutics PLC News
New
European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading
European equities traded in the US as American depositary receipts were moving higher late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
European equities traded in the US as American depositary receipts were little changed late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading
European equities traded in the US as American depositary receipts were down significantly late Tues PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
European equities traded in the US as American depositary receipts opened the week on a flat note Mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Akari Therapeutics PLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
